{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T07:51:40Z","timestamp":1773474700101,"version":"3.50.1"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejps.2026.107478","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:25:37Z","timestamp":1771374337000},"page":"107478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Toward optimal moxifloxacin dosing in tuberculous meningitis: A translational physiologically based pharmacokinetic modeling approach"],"prefix":"10.1016","volume":"220","author":[{"given":"Ming","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theis","family":"Mariager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Bodilsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Nau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob C.","family":"van Wijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martijn L.","family":"Manson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth C.M.","family":"de Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8018-1152","authenticated-orcid":false,"given":"Tingjie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejps.2026.107478_bib0024","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1128\/AAC.01637-07","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis","volume":"52","author":"Alffenaar","year":"2008","journal-title":"Antimicrob. Agents Chemother"},{"issue":"7","key":"10.1016\/j.ejps.2026.107478_bib0004","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1086\/605576","article-title":"Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis","volume":"49","author":"Alffenaar","year":"2009","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.ejps.2026.107478_bib0039","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/jac\/dkq091","article-title":"Wild-type MIC distributions of four fluoroquinolones active against mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data","volume":"65","author":"Angeby","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.ejps.2026.107478_bib0017","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2174\/156652409787581655","article-title":"Pathogenesis of central nervous system tuberculosis","volume":"9","author":"Be","year":"2009","journal-title":"Curr. Mol. Med."},{"issue":"1","key":"10.1016\/j.ejps.2026.107478_bib0058","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12987-022-00401-4","article-title":"Characterising spinal cerebrospinal fluid flow in the pig with phase-contrast magnetic resonance imaging","volume":"20","author":"Bessen","year":"2023","journal-title":"Fluids Barriers CNS."},{"issue":"10","key":"10.1016\/j.ejps.2026.107478_bib0043","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.3390\/antibiotics11101293","article-title":"A minimal physiologically based pharmacokinetic model to characterize CNS distribution of metronidazole in Neuro care ICU patients","volume":"11","author":"Chauzy","year":"2022","journal-title":"Antibiotics"},{"issue":"6","key":"10.1016\/j.ejps.2026.107478_bib0053","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/sj.bjp.0706389","article-title":"QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome","volume":"146","author":"Chen","year":"2005","journal-title":"Br. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.ejps.2026.107478_bib0002","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S1473-3099(14)70852-7","article-title":"Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis","volume":"14","author":"Chiang","year":"2014","journal-title":"Lancet Infect. Dis."},{"issue":"3","key":"10.1016\/j.ejps.2026.107478_bib0036","article-title":"Optimizing moxifloxacin dose in MDR-TB participants with or without Efavirenz coadministration using population pharmacokinetic modeling","volume":"67","author":"Chirehwa","year":"2023","journal-title":"Antimicrob. Agents Chemother"},{"issue":"1","key":"10.1016\/j.ejps.2026.107478_bib0059","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/jor.23448","article-title":"Cerebrospinal fluid dynamics at the lumbosacral level in patients with spinal stenosis: a pilot study","volume":"35","author":"Chun","year":"2017","journal-title":"J. Orthop. Res."},{"issue":"3","key":"10.1016\/j.ejps.2026.107478_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0315999","article-title":"Pharmacometabolomics in TB meningitis-understanding the pharmacokinetic, metabolic, and immune factors associated with anti-TB drug concentrations in cerebrospinal fluid","volume":"20","author":"Collins","year":"2025","journal-title":"PLoS. One"},{"issue":"2","key":"10.1016\/j.ejps.2026.107478_bib0057","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1152\/physrev.1971.51.2.273","article-title":"Physiology of the choroid plexus","volume":"51","author":"Cserr","year":"1971","journal-title":"Physiol. Rev."},{"issue":"2","key":"10.1016\/j.ejps.2026.107478_bib0066","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/JLB.MR0318-102R","article-title":"The pathogenesis of tuberculous meningitis","volume":"105","author":"Davis","year":"2019","journal-title":"J. Leukoc. Biol."},{"issue":"8","key":"10.1016\/j.ejps.2026.107478_bib0006","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1093\/cid\/ciac932","article-title":"A phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for Human Immunodeficiency Virus\u2013associated tuberculous meningitis: the LASER-TBM trial","volume":"76","author":"Davis","year":"2022","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.ejps.2026.107478_bib0013","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.tube.2010.07.002","article-title":"Cerebrospinal fluid concentrations of antituberculosis agents in adults and children","volume":"90","author":"Donald","year":"2010","journal-title":"Tuberculosis. (Edinb)"},{"issue":"18","key":"10.1016\/j.ejps.2026.107478_bib0011","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"New England J. Med."},{"issue":"3","key":"10.1016\/j.ejps.2026.107478_bib0054","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00139-10","article-title":"The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of mycobacterium tuberculosis as determined in a hollow-fiber infection model","volume":"1","author":"Drusano","year":"2010","journal-title":"mBio"},{"issue":"10","key":"10.1016\/j.ejps.2026.107478_bib0018","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/jps.2600721003","article-title":"Physiologically based pharmacokinetic modeling: principles and applications","volume":"72","author":"Gerlowski","year":"1983","journal-title":"J. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.ejps.2026.107478_bib0035","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1086\/424849","article-title":"Selection of a moxifloxacin dose that suppresses drug resistance in mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling","volume":"190","author":"Gumbo","year":"2004","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.ejps.2026.107478_bib0005","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1056\/NEJMoa1507062","article-title":"Intensified antituberculosis therapy in adults with tuberculous meningitis","volume":"374","author":"Heemskerk","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ejps.2026.107478_bib0060","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14091764","article-title":"Revisiting cerebrospinal fluid flow direction and rate in physiologically based pharmacokinetic model","volume":"14","author":"Hirasawa","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ejps.2026.107478_bib0061","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/2045-8118-11-26","article-title":"Mechanisms of fluid movement into, through and out of the brain: evaluation of the evidence","volume":"11","author":"Hladky","year":"2014","journal-title":"Fluids Barriers CNS"},{"issue":"3","key":"10.1016\/j.ejps.2026.107478_bib0042","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jac\/dkae025","article-title":"Linezolid brain penetration in neurointensive care patients","volume":"79","author":"Hosmann","year":"2024","journal-title":"J. Antimicrob. Chemother"},{"issue":"6","key":"10.1016\/j.ejps.2026.107478_bib0021","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/jac\/dkn110","article-title":"Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect","volume":"61","author":"Kanellakopoulou","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2026.107478_bib0064","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1741-7007-5-18","article-title":"Global and regional brain metabolic scaling and its functional consequences","volume":"5","author":"Karbowski","year":"2007","journal-title":"BMC Biol."},{"key":"10.1016\/j.ejps.2026.107478_bib0062","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.neuroscience.2019.06.032","article-title":"The movement of cerebrospinal fluid and its relationship with substances behavior in cerebrospinal and interstitial fluid","volume":"414","author":"Klarica","year":"2019","journal-title":"Neuroscience"},{"issue":"9","key":"10.1016\/j.ejps.2026.107478_bib0028","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1002\/jps.24398","article-title":"Quantitative determination of luminal and abluminal membrane distributions of transporters in Porcine brain capillaries by plasma membrane fractionation and Quantitative targeted proteomics","volume":"104","author":"Kubo","year":"2015","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejps.2026.107478_bib0063","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12987-022-00323-1","article-title":"Cerebrospinal fluid production by the choroid plexus: a century of barrier research revisited","volume":"19","author":"MacAulay","year":"2022","journal-title":"Fluids Barriers CNS"},{"issue":"3","key":"10.1016\/j.ejps.2026.107478_bib0055","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01771-20","article-title":"Tuberculous meningitis: pathogenesis, immune responses, diagnostic challenges, and the potential of biomarker-based approaches","volume":"59","author":"Manyelo","year":"2021","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.ejps.2026.107478_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1048653","article-title":"Cerebrospinal fluid concentrations of fluoroquinolones and carbapenems in tuberculosis meningitis","volume":"13","author":"Maranchick","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejps.2026.107478_bib0020","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/jac\/dkae098","article-title":"Continuous evaluation of single-dose moxifloxacin concentrations in brain extracellular fluid, cerebrospinal fluid, and plasma: a novel porcine model","volume":"79","author":"Mariager","year":"2024","journal-title":"J. Antimicrob. Chemother"},{"issue":"8","key":"10.1016\/j.ejps.2026.107478_bib0047","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.38.8.1849","article-title":"Kinetics of ofloxacin and its metabolites in cerebrospinal fluid after a single intravenous infusion of 400 milligrams of ofloxacin","volume":"38","author":"Nau","year":"1994","journal-title":"Antimicrob. Agents Chemother"},{"issue":"4","key":"10.1016\/j.ejps.2026.107478_bib0009","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/CMR.00007-10","article-title":"Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections","volume":"23","author":"Nau","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"issue":"8","key":"10.1016\/j.ejps.2026.107478_bib0056","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11082165","article-title":"The pig as a translational animal model for biobehavioral and neurotrauma research","volume":"11","author":"Netzley","year":"2023","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.ejps.2026.107478_bib0034","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/psp4.12161","article-title":"Model evaluation of continuous data pharmacometric models: metrics and graphics","volume":"6","author":"Nguyen","year":"2017","journal-title":"CPT Pharmacometrics. Syst. Pharmacol."},{"issue":"8","key":"10.1016\/j.ejps.2026.107478_bib0012","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1086\/521894","article-title":"Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis","volume":"45","author":"Nijland","year":"2007","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.ejps.2026.107478_bib0008","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1164\/rccm.200310-1380OC","article-title":"Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis","volume":"169","author":"Nuermberger","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.ejps.2026.107478_bib0046","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1128\/AAC.33.6.933","article-title":"Diffusion of ofloxacin into cerebrospinal fluid of patients with purulent meningitis or ventriculitis","volume":"33","author":"Pioget","year":"1989","journal-title":"Antimicrob. Agents Chemother"},{"issue":"3","key":"10.1016\/j.ejps.2026.107478_bib0023","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jat\/34.3.135","article-title":"Determination of moxifloxacin in human plasma, plasma ultrafiltrate, and cerebrospinal fluid by a rapid and simple liquid chromatography- tandem mass spectrometry method","volume":"34","author":"Pranger","year":"2010","journal-title":"J. Anal. Toxicol."},{"issue":"6","key":"10.1016\/j.ejps.2026.107478_bib0007","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0924-8579(02)00239-X","article-title":"In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against mycobacterium tuberculosis","volume":"20","author":"Rodr\u00edguez","year":"2002","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"1","key":"10.1016\/j.ejps.2026.107478_bib0048","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(12)70264-5","article-title":"Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial","volume":"13","author":"Ruslami","year":"2013","journal-title":"Lancet Infect. Dis."},{"issue":"8","key":"10.1016\/j.ejps.2026.107478_bib0051","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1124\/dmd.109.027441","article-title":"Selective role of sulfotransferase 2A1 (SULT2A1) in the N-sulfoconjugation of quinolone drugs in humans","volume":"37","author":"Senggunprai","year":"2009","journal-title":"Drug Metab. Dispos."},{"issue":"Pt 16","key":"10.1016\/j.ejps.2026.107478_bib0030","first-page":"2631","article-title":"Scaling of cerebral blood perfusion in primates and marsupials","volume":"218","author":"Seymour","year":"2015","journal-title":"J. Exp. Biol."},{"issue":"4","key":"10.1016\/j.ejps.2026.107478_bib0045","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM197507242930402","article-title":"Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections","volume":"293","author":"Shapiro","year":"1975","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejps.2026.107478_bib0052","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1021\/mp200129p","article-title":"Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels","volume":"8","author":"Shawahna","year":"2011","journal-title":"Mol. Pharm."},{"issue":"Suppl B","key":"10.1016\/j.ejps.2026.107478_bib0026","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jac\/43.suppl_2.69","article-title":"Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species","volume":"43","author":"Siefert","year":"1999","journal-title":"J. Antimicrob. Chemother"},{"key":"10.1016\/j.ejps.2026.107478_bib0040","unstructured":"Simulations Plus. Monolix. 2024."},{"issue":"8","key":"10.1016\/j.ejps.2026.107478_bib0001","doi-asserted-by":"crossref","first-page":"ofaa257","DOI":"10.1093\/ofid\/ofaa257","article-title":"Treatment outcomes in adult tuberculous meningitis: a systematic review and meta-analysis","volume":"7","author":"Stadelman","year":"2020","journal-title":"Open. Forum. Infect. Dis."},{"issue":"8","key":"10.1016\/j.ejps.2026.107478_bib0065","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1128\/AAC.42.8.2060","article-title":"Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects","volume":"42","author":"Stass","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.ejps.2026.107478_bib0003","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/bmb\/ldv003","article-title":"Tuberculous meningitis: advances in diagnosis and treatment","volume":"113","author":"T\u00f6r\u00f6k","year":"2015","journal-title":"Br. Med. Bull."},{"issue":"6","key":"10.1016\/j.ejps.2026.107478_bib0050","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1124\/dmd.104.003178","article-title":"Acyl glucuronidation of fluoroquinolone antibiotics by the UDP-glucuronosyltransferase 1A subfamily in human liver microsomes","volume":"33","author":"Tachibana","year":"2005","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.ejps.2026.107478_bib0067","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/jnnp.68.3.289","article-title":"Tuberculous meningitis","volume":"68","author":"Thwaites","year":"2000","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.ejps.2026.107478_bib0027","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/jnc.13147","article-title":"Quantitative targeted absolute proteomics of rat blood-cerebrospinal fluid barrier transporters: comparison with a human specimen","volume":"134","author":"Uchida","year":"2015","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.ejps.2026.107478_bib0029","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1124\/dmd.119.089516","article-title":"Abundant expression of OCT2, MATE1, OAT1, OAT3, PEPT2, BCRP, MDR1, and xCT transporters in blood-arachnoid barrier of pig and polarized localizations at CSF- and blood-facing plasma membranes","volume":"48","author":"Uchida","year":"2020","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.ejps.2026.107478_bib0022","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1128\/JCM.01473-08","article-title":"Evolution of central nervous system multidrug-resistant mycobacterium tuberculosis and late relapse of cryptic prosthetic hip joint tuberculosis: complications during treatment of disseminated isoniazid-resistant tuberculosis in an immunocompromised host","volume":"47","author":"Upton","year":"2009","journal-title":"J. Clin. Microbiol."},{"issue":"7","key":"10.1016\/j.ejps.2026.107478_bib0033","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00384-19","article-title":"Limited sampling strategies using linear regression and the Bayesian approach for therapeutic drug monitoring of moxifloxacin in tuberculosis patients","volume":"63","author":"van den Elsen","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.ejps.2026.107478_bib0049","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/cpt.2652","article-title":"Rifampin drug-drug-interaction studies: reflections on the nitrosamine impurities issue","volume":"113","author":"van Haarst","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.ejps.2026.107478_bib0032","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01829-21","article-title":"Clinical relevance of rifampicin-moxifloxacin interaction in isoniazid-resistant\/intolerant tuberculosis patients","volume":"66","author":"Vogensen","year":"2022","journal-title":"Antimicrob. Agents Chemother"},{"issue":"1","key":"10.1016\/j.ejps.2026.107478_bib0041","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/psp4.12052","article-title":"A tutorial on RxODE: simulating differential equation pharmacometric models in R","volume":"5","author":"Wang","year":"2016","journal-title":"CPT Pharmacometrics. Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2026.107478_bib0044","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejps.2013.12.020","article-title":"Prediction of methotrexate CNS distribution in different species - influence of disease conditions","volume":"57","author":"Westerhout","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107478_bib0010","series-title":"WHO Consolidated Guidelines On Drug-Resistant Tuberculosis Treatment","first-page":"2019","year":"2019"},{"issue":"10","key":"10.1016\/j.ejps.2026.107478_bib0016","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrneurol.2017.120","article-title":"Tuberculous meningitis","volume":"13","author":"Wilkinson","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejps.2026.107478_bib0031","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fneng.2013.00007","article-title":"The blood-brain barrier: an engineering perspective","volume":"6","author":"Wong","year":"2013","journal-title":"Front. Neuroeng."},{"key":"10.1016\/j.ejps.2026.107478_bib0019","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejps.2017.11.011","article-title":"Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach","volume":"112","author":"Yamamoto","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ejps.2026.107478_bib0037","doi-asserted-by":"crossref","first-page":"ofab660","DOI":"10.1093\/ofid\/ofab660","article-title":"Model-based efficacy and toxicity comparisons of moxifloxacin for multidrug-resistant tuberculosis","volume":"9","author":"Yun","year":"2022","journal-title":"Open. Forum. Infect. Dis."},{"issue":"1","key":"10.1016\/j.ejps.2026.107478_bib0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003495-200262010-00002","article-title":"A critical review of the fluoroquinolones: focus on respiratory infections","volume":"62","author":"Zhanel","year":"2002","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ejps.2026.107478_bib0038","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1128\/AAC.01478-13","article-title":"Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients","volume":"58","author":"Zvada","year":"2014","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726000527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726000527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T07:14:10Z","timestamp":1773472450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098726000527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":67,"alternative-id":["S0928098726000527"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107478","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toward optimal moxifloxacin dosing in tuberculous meningitis: A translational physiologically based pharmacokinetic modeling approach","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107478","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107478"}}